A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)
Date
2016Author
Yap, Timothy AnthonyWinter, Jane N.
Leonard, John P.
Ribrag, Vincent
Constantinidou, Anastasia
Giulino-Roth, Lisa
Michot, Jean-Marie
Khan, Tariq A.
Horner, Thierry
Carver, Jennifer
Dumetrescu, Teodora Pene
He, Zangdong
McCabe, Michael T.
Creasy, Caretha L.
Dhar, Arindam
Carpenter, Christopher
Johnson, Peter M.
Source
BloodVolume
128Issue
22Google Scholar check